



IFFIm earns A+ rating from FCDO



Since 2006, IFFIm has been a critical player in Gavi's financial strategy and its main source of long-term, flexible funding for Gavi 5.0. IFFIm earned an A+ score in the most recent evaluation from the United Kingdom's Foreign, Commonwealth & Development Office (FCDO) "reflecting the continued strong performance of IFFIm over 2021 and 2022 supporting Gavi's implementation."

[Read more](#)



Here's how the meningitis vaccine works

IFFIm supports Gavi's meningitis programmes with funding of US\$ 108 million.

Latest articles



Gavi report highlights rebound in routine immunisation

In its latest Annual Progress Report, Gavi reveals that basic childhood immunisation rebounded in 2022 as lower-income countries collectively contributed US\$ 162 million to co-finance Gavi-supported vaccines, the highest amount in their 23-year history.

[Read more](#)



IFFIm funding helps #VaccinesWork

Gavi and IFFIm invest in vaccines to fight measles, pneumococcus, rotavirus and yellow fever.

[Read more](#)




IFFIm donors gather for annual meeting

At the October gathering, donors expressed support for IFFIm initiatives that extend Gavi's financial strength and help the world prepare for future pandemics.

[Read more](#)

Other news



IFFIm rating

- **October 2023:** Moody's affirms IFFIm's Aa1 rating and changes outlook to stable from negative, in line with their change of the UK outlook to stable from negative.
- **June 2023:** Fitch affirms IFFIm at 'AA-'; outlook negative.

[Read more](#)